On Nov. 5, 2007, the U.S. Food and Drug Administration announced that Bayer Pharmaceuticals Corp. agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery. At that time, preliminary results from a Canadian study suggested an increased risk for death compared to two other drugs used to control bleeding. Bayer HealthCare Pharmaceuticals Inc. has notified the FDA that the company will begin removing the remaining Trasylol stock from the U.S. market, most of which is in warehouses and hospital or physician’s stock. The FDA will work with Bayer to ensure a smooth and complete process.
Recallr: Bayer HealthCare Pharmaceuticals Inc. Removes Remaining Stocks of Trasylol From US MarketTags:
FDA Recall, Drug Recall, Trasylol recall, Trasylol marketing suspension, Bayer Recall , Trasylol, FDA, Antifibrinolytic drugs, Bayer Pharmaceuticals Corp
No comments:
Post a Comment